Hilas O, Avena-Woods C (2014) Potential role of mirtazapine in underweight older adults. Consult

Pharm 29(2):124–130

Hilmer SN (2008) ADME-tox issues for the elderly. Expert Opin Drug Metab Toxicol 4(10):

1321–1331

Hines LE, Murphy JE (2011) Potentially harmful drug-drug interactions in the elderly: a review.

Am J Geriatr Pharmacother 9(6):364–377

Hoek FJ, Kemperman FA, Krediet RT (2003) A comparison between cystatin C, plasma creatinine

and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol

Dial Transplant 18(10):2024–2031

Hojs R, Bevc S, Ekart R, Gorenjak M, Puklavec L (2010) Serum cystatin C-based formulas for

prediction of glomerular filtration rate in patients with chronic kidney disease. Nephron Clin

Pract 114(2):c118–c126

Holick MF, Matsuoka LY, Wortsman J (1989) Age, vitamin D, and solar ultraviolet. Lancet

2(8671):1104–1105

Holper L (2020) Optimal doses of antidepressants in dependence of age: combined covariate

actions in Bayesian network meta-analysis. E-Clin Med 18:100219. Published online 2020

Jan 7. https://doi.org/10.1016/j.eclinm.2019.11.012

Hosia-Randell HM, Muurinen SM, Pitkala KH (2008) Exposure to potentially inappropriate drugs

and drug-drug interactions in elderly nursing home residents in Helsinki, Finland: a cross-

sectional study. Drugs Aging 25(8):683–692

Hurwitz A, Brady DA, Schaal SE, Samloff IM, Dedon J, Ruhl CE (1997) Gastric acidity in older

adults. JAMA 278(8):659–662

Italiano D, Perucca E (2013) Clinical pharmacokinetics of new-generation antiepileptic drugs at the

extremes of age: an update. Clin Pharmacokinet 52(8):627–645

Jin Y, Pollock BG, Frank E, Cassano GB, Rucci P, Müller DJ, Kennedy JL, Forgione RN,

Kirshner M, Kepple G, Fagiolini A, Kupfer DJ, Bies RR (2010) Effect of age, weight and

CYP2C19 genotype on escitalopram exposure. J Clin Pharmacol 50(1):62–72

Kaestli L-Z, Wasilewski-Rasca A-F, Bonnabry P, Vogt-Ferrier N (2008) Use of transdermal drug

formulations in the elderly. Drugs Aging 25(4):269–280

Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH (1989) A

review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand

Suppl 350:60–75

Kim S, Jazwinski SM (2018) The gut microbiota and healthy aging. Gerontology 64(6):513–520

Knadler MP, Lobo E, Chappell J, Bergstrom R (2011) Duloxetine: clinical pharmacokinetics and

drug interactions. Clin Pharmacokinet 50(5):281–294

Kragh-Sorensen P, Larsen NE (1980) Factors influencing nortriptyline steady-state kinetics: plasma

and saliva levels. Clin Pharmacol Ther 28(6):796–803

Kratz T, Diefenbacher A (2019) Psychopharmacological treatment of older people. Dtsch Arztebl

Int 116:508–518

Kutcher SP, Reid K, Dubbin JD, Shulman KI (1986) Electrocardiogram changes and therapeutic

desipramine and 2-hydroxy-desipramine concentrations in elderly depressives. Br J Psychiatry

148:676–679

Lam YWF, Scott SA (2019) Pharmacogenomics. In: Challenges and opportunities in therapeutoc

implementation, 2nd edn. Academic Press (Elsevier), London, UK

Larsson A, Malm J, Grubb A, Hansson LO (2004) Calculation of glomerular filtration rate

expressed in mL/min from plasma cystatin C values in mg/L. Scand J Clin Lab Invest 64(1):

25–30

Lenander C, Bondesson A, Viberg N, Beckman A, Midlöv P (2018) Effects of medication reviews

on use of potentially inappropriate medication use in elderly: a cross-secional study in Swedish

primary care. BMC Health Serv Res 18(1):616. https://doi.org/10.1186/s12913-018-3425-y

Lozano R, Bibian C, Quilez R-M, Gil J, Constante Y, Garcia-Arilla E (2013) Clinical relevance of

the (S)-citalopram-omeprazole interaction in geriatric patients. Br J Clin Pharmacol 77(6):

1086–1087

268

M. Bhaskar et al.